TY - JOUR
T1 - Antithrombotic treatment for symptomatic peripheral artery disease
AU - Li, Yi Heng
AU - Yeh, Hung I.
AU - Hwang, Juey Jen
N1 - Publisher Copyright:
© 2019, Republic of China Society of Cardiology. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Single antiplatelet therapy with aspirin or clopidogrel is widely used in the prevention of adverse cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD). However, the risk of these events remains high, and the most optimal antithrombotic therapy for PAD is still uncertain. We conducted a literature search to identify the major clinical trials on therapeutic approaches in the prevention of adverse events in patients with PAD. This article provides an overview of the clinical trials that have evaluated the efficacy and safety of intensified antithrombotic strategies for PAD. Due to the heterogeneity of patient populations and the variable definitions of clinical outcomes used in different clinical studies, it was difficult to make direct comparisons between the study results. Although a number of choices are now available, the risk-benefit of each antithrombotic regimen for patients with PAD must be carefully considered.
AB - Single antiplatelet therapy with aspirin or clopidogrel is widely used in the prevention of adverse cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD). However, the risk of these events remains high, and the most optimal antithrombotic therapy for PAD is still uncertain. We conducted a literature search to identify the major clinical trials on therapeutic approaches in the prevention of adverse events in patients with PAD. This article provides an overview of the clinical trials that have evaluated the efficacy and safety of intensified antithrombotic strategies for PAD. Due to the heterogeneity of patient populations and the variable definitions of clinical outcomes used in different clinical studies, it was difficult to make direct comparisons between the study results. Although a number of choices are now available, the risk-benefit of each antithrombotic regimen for patients with PAD must be carefully considered.
UR - http://www.scopus.com/inward/record.url?scp=85075073023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075073023&partnerID=8YFLogxK
U2 - 10.6515/ACS.201911_35(6).20190907A
DO - 10.6515/ACS.201911_35(6).20190907A
M3 - Review article
AN - SCOPUS:85075073023
SN - 1011-6842
VL - 35
SP - 557
EP - 562
JO - Acta Cardiologica Sinica
JF - Acta Cardiologica Sinica
IS - 6
ER -